Which marker is included in the IHC panel for primary gastric adenocarcinoma?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Prepare for the CMID Test. Study with flashcards and multiple choice questions, each question contains hints and explanations. Get ready for your exam with confidence!

Multiple Choice

Which marker is included in the IHC panel for primary gastric adenocarcinoma?

Explanation:
PD-L1 testing by IHC is used in gastric adenocarcinoma to guide immunotherapy with PD-1/PD-L1 inhibitors. PD-L1 is expressed on tumor and immune cells, and the IHC result helps identify patients who may benefit from treatments like pembrolizumab in certain settings. The other markers don’t fit this context: GFAP is a glial cell marker used in CNS tumors, PSMA is linked to prostate cancer, and CEA is mainly a serum tumor marker rather than an IHC target used to guide immunotherapy in gastric cancer.

PD-L1 testing by IHC is used in gastric adenocarcinoma to guide immunotherapy with PD-1/PD-L1 inhibitors. PD-L1 is expressed on tumor and immune cells, and the IHC result helps identify patients who may benefit from treatments like pembrolizumab in certain settings. The other markers don’t fit this context: GFAP is a glial cell marker used in CNS tumors, PSMA is linked to prostate cancer, and CEA is mainly a serum tumor marker rather than an IHC target used to guide immunotherapy in gastric cancer.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy